Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVTR 
Avantor Inc (AVTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: AVTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $14.12
1 Year Target Price $14.12
| 6 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.13% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.25B USD | Price to earnings Ratio 11.98 | 1Y Target Price 14.12 |
Price to earnings Ratio 11.98 | 1Y Target Price 14.12 | ||
Volume (30-day avg) 21 | Beta 0.96 | 52 Weeks Range 10.82 - 27.83 | Updated Date 08/12/2025 |
52 Weeks Range 10.82 - 27.83 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-24 | When Before Market | Estimate 0.2477 | Actual 0.24 |
Profitability
Profit Margin 10.31% | Operating Margin (TTM) 7.63% |
Management Effectiveness
Return on Assets (TTM) 3.24% | Return on Equity (TTM) 11.73% |
Valuation
Trailing PE 11.98 | Forward PE 12.84 | Enterprise Value 12042137967 | Price to Sales(TTM) 1.24 |
Enterprise Value 12042137967 | Price to Sales(TTM) 1.24 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA 8.53 | Shares Outstanding 681739008 | Shares Floating 664211174 |
Shares Outstanding 681739008 | Shares Floating 664211174 | ||
Percent Insiders 1.34 | Percent Institutions 100.21 |
Upturn AI SWOT
Avantor Inc
Company Overview
History and Background
Avantor, Inc. traces its roots back to 1904 with the founding of J.T. Baker Chemical Company. Over the years, it has evolved through mergers and acquisitions, becoming a leading global provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries.
Core Business Areas
- Materials and Consumables: This segment provides a comprehensive range of high-purity materials, chemicals, lab supplies, and consumables used in research, development, and manufacturing.
- Lab and Production Equipment: This segment offers lab equipment, instruments, and automation solutions used in various stages of scientific research and biopharmaceutical production.
- Services and Specialty Procurement: This segment encompasses a suite of services including lab services, single-use solutions, and specialized procurement offerings to support customers' operational needs.
Leadership and Structure
Avantor is led by a Chief Executive Officer (CEO) and a management team overseeing various functional areas. The company has a global organizational structure with regional operations and business unit divisions.
Top Products and Market Share
Key Offerings
- Competitors: Merck KGaA (MKKGY),Thermo Fisher Scientific (TMO)
- High-Purity Chemicals: Avantor provides a wide range of high-purity chemicals used in various industries, including biopharma and electronics. Competitors include Merck KGaA (MKKGY) and Thermo Fisher Scientific (TMO). Market share is difficult to pinpoint precisely, but they are a significant player in this space, with revenue in the billions.
- Competitors: Sartorius (SARTF),Danaher (DHR)
- Single-Use Solutions: These products are critical for biopharmaceutical manufacturing, offering sterile fluid handling and containment systems. Competitors include Sartorius (SARTF) and Danaher (DHR). Again, specific market share data is sensitive, but single-use solutions contribute significantly to their overall revenue.
- Competitors: Thermo Fisher Scientific (TMO)
- Laboratory Equipment: Avantor also supplies a wide range of laboratory equipment including centrifuges, freezers, incubators etc. Competitors include Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The life sciences and advanced technologies industries are experiencing growth driven by increasing R&D spending, advancements in biopharmaceuticals, and growing demand for advanced materials.
Positioning
Avantor is positioned as a leading provider of critical products and services to these industries, with a focus on high-quality products, customized solutions, and global reach.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the hundreds of billions of dollars. Avantor holds a significant position within the market but is only one of several major players.
Upturn SWOT Analysis
Strengths
- Global Scale and Reach
- Broad Product Portfolio
- Strong Customer Relationships
- Focus on Innovation
- Established Brand Reputation
Weaknesses
- Integration Risks from Acquisitions
- Exposure to Economic Cycles
- Dependence on Key Suppliers
- Complexity of Global Operations
- High Debt Levels
Opportunities
- Expanding into Emerging Markets
- Growing Demand for Biopharmaceuticals
- Increasing R&D Spending
- Developing New Products and Services
- Acquiring Complementary Businesses
Threats
- Increased Competition
- Changing Regulatory Landscape
- Economic Downturns
- Supply Chain Disruptions
- Pricing Pressures
Competitors and Market Share
Key Competitors
- TMO
- DHR
- MRK
- SYK
Competitive Landscape
Avantor benefits from its broad product portfolio and global reach, but faces competition from larger, more diversified companies like Thermo Fisher Scientific and Danaher.
Major Acquisitions
Masterflex
- Year: 2021
- Acquisition Price (USD millions): 2300
- Strategic Rationale: Expanded biopharma capabilities and single-use fluid technology.
RIM Bio
- Year: 2021
- Acquisition Price (USD millions): 23
- Strategic Rationale: Expanded services in China
Growth Trajectory and Initiatives
Historical Growth: Avantor has grown both organically and through acquisitions.
Future Projections: Analysts project continued growth in revenue and earnings, driven by demand in the biopharma and advanced technologies industries.
Recent Initiatives: Recent initiatives include acquisitions to expand product offerings and geographic reach, as well as investments in innovation and operational efficiency.
Summary
Avantor is a key player in the life sciences and advanced technology industries, offering a wide range of products and services. They have grown substantially through acquisitions and organic initiatives, positioning the company for continued growth. However, high debt levels and integration risks remain concerns, and they operate in a competitive environment. Future success depends on innovation and effective execution of their growth strategy.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Market research reports
- Analyst estimates
- Company Investor Relations
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Financial data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avantor Inc
Exchange NYSE | Headquaters Radnor, PA, United States | ||
IPO Launch date 2019-05-17 | President, CEO & Director Mr. Michael Stubblefield | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.avantorsciences.com |
Full time employees 13500 | Website https://www.avantorsciences.com | ||
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.